Bachem signs long-term manufacturing, supply agreement for peptides
The order covers a committed volume at an equivalent value of over CHF 500 million for the five-year period of 2027-2031, with significant upside potential.
- By ICN Bureau
| March 06, 2023
Bachem Group recently announced that it has signed a new framework agreement to provide large volumes of peptides following a joint development project. Manufacturing is to primarily occur at Bachem’s new large-scale production facility (Building “K”) currently under construction in Bubendorf. The order covers a committed volume at an equivalent value of over CHF 500 million for the five-year period of 2027-2031, with significant upside potential.
The companies have agreed not to disclose additional details and respect customer confidentiality.
"Bachem is making a major contribution to supplying the pharmaceutical and biotechnology industries with complex active ingredients for medicines. I am pleased that with this new and important development and supply agreement, we can further diversify our portfolio of long-term customer projects. We are currently addressing the growing global demand for peptide production capacities with an extensive investment program." said Thomas Meier, CEO, Bachem Group.
Bachem is pursuing an investment program across all sites to expand capacity. The company is constructing a modern large-scale facility for the manufacture of peptides and oligonucleotides at its Bubendorf site (Building «K» – TIDES FABrication Plant) with the potential to double the manufacturing capacity at the site. The facility is scheduled to open in 2024. In October 2022, Bachem further announced its purchase of land for a third site in Switzerland in Eiken, Canton of Aargau, which is intended to further strengthen the production network from the end of the decade onward. Bachem is also investing in capacity expansion across its global manufacturing network at sites in Vionnaz (Switzerland), Torrance (USA), Vista (USA), and St. Helens (UK).